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This study was designed to evaluate utilization patterns and clinical outcome of intravenous 
immunoglobulin (IVIG) therapy among pediatric patients in a tertiary hospital. Demographic data, 
IVIG prescribed, and clinical outcome were retrospectively reviewed from the pharmacy dispensing 
data and patient medical records between 2007 and 2014. One hundred and fifteen instances of IVIG 
administration to 108 pediatric patients were recorded. A total of 61 cases (53%) and 54 cases (47%) of 
the IVIG administered were for labeled and off-labeled indications, respectively. Age, weight, specialty, 
total IVIG usage, length of hospital stays, and mortality rate were found to be significantly associated 
with the indication being labeled or off-labeled (p<0.05). However, there was no significant difference 
in terms of adverse reactions between labeled and off-labeled indications (p>0.05). Guidelines should be 
developed and implemented for rational and evidence-based use of IVIG to avoid unnecessary wastage.
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INTRODUCTION 
Over the past  two and a half  decades,  the 
administration of intravenous immunoglobulin (IVIG) has 
become an important therapy in clinical medicine. These 
preparations, which contain a broad range of antibody 
specificities, were originally used in antibody replacement 
therapy. However, many other clinical benefits of IVIG 
treatment have been demonstrated (Orange et al., 2006). 
A rapid increase in the use of IVIG for an ever-growing 
number of conditions in children and neonates was also 
reported (Stiehm, Keller, Vyas, 2008). 
In pediatrics, IVIG has been found to have a major 
impact in the treatment of conditions in the fields of 
neurology, hematology, rheumatology, dermatology, 
neonatology, immunology, cardiology, and infectious 
diseases (Prasad, Chaudhary, 2014). More than 150 off-
labeled indications of IVIG in 128 clinical trials and 268 
case reports were reported in another literature review 
by Leong et al. (2008). The most common off-labeled 
indications include multiple sclerosis, prevention of 
antiphospholipid syndrome in miscarriage, Guillain-Barré 
syndrome, and progression of human immunodeficiency 
virus (HIV) after delivery. Health care institutions are 
strongly urged to closely monitor specific uses of IVIG 
to reserve supplies for the “best-evidence” uses because 
of the limited knowledge associated with off-labeled 
indications (Leong et al., 2008).
IVIG is known to be a complex therapy with 
adverse effects. Adverse reactions associated with the 
regular administration of IVIG still occur despite the 
introduction of manufacturing steps that enhance purity, 
minimize damage to the Immunoglobulin G molecules, 
and result in a higher concentration of liquid IVIG 
(Bichuetti-Silva et al., 2014). In 2002, a survey of more 
than 1000 patients with primary immunodeficiency 
conducted by the Immune Deficiency Foundation (IDF) 
found that 44% of the reported adverse reactions were 
not related to the rate of infusion but to the drug itself. 
Systemic reactions to IVIG infusion (not related to the 
rate of infusion) were reported to range from 3% to 15%, 
which include backache, abdominal pain, nausea, chills, 
rhinitis, asthma, low-grade fever, myalgia, and headaches 
(Goddard, 2008). 
This study was designed to evaluate utilization 
patterns and clinical outcome of the IVIG therapy in a 
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tertiary teaching hospital in Malaysia focusing on the off-
label indications.
MATERIAL AND METHODS 
This observational retrospective chart review study 
was approved by the Research Ethics Committee of 
UKMMC (UKM 1.5.3.5/244/NF-009-15). Data collection 
was carried out from April to June 2015. Pediatric 
patients ranging in age from birth to 12 years who were 
administered IVIG from January 2007 to December 2014 
during their hospital stay were traced using the IVIG usage 
logbook at the pharmacy department of UKMMC. Medical 
records were then retrieved from the Medical Record Unit 
and screened for confirmation of IVIG administration. 
Detailed clinical data including demographic data, primary 
diagnosis, dosing regimen of IVIG, indication, and clinical 
outcome were recorded using a designated data collection 
form. 
The indication of IVIG is mainly divided into two 
categories, labeled and off-labeled. Labeled indication 
refers to the seven indications approved by the FDA as 
follows:
a. Treatment of primary immunodeficiency
b. Prevention of bacterial infections in patients with 
hypogammaglobulinemia and recurrent infection 
caused by B-cell chronic lymphocytic leukemia
c. Prevention of coronary artery aneurysms in Kawa-
saki disease
d. Prevention of infections, pneumonia, and acute graft 
versus host disease (GVHD) after bone marrow 
transplantation
e. Reduction of serious bacterial infection in children 
with HIV
f. Increase of platelet count in idiopathic thrombocy-
topenic purpura (ITP) to prevent or control bleeding
g. Chronic inflammatory demyelinating polyneuropa-
thy (CIDP)
Appropriate use of IVIG was placed into one of three 
a priori agreed upon categories. Off-labeled indication 
is defined as the indication of IVIG other than the seven 
indications approved by the FDA (Prasad, Chaudhary, 
2014). Off-labeled indication is further categorized into 
2 subgroups, “potentially indicated” or “not indicated.” 
“Off-labeled, potentially indicated” is the term used 
for disorders with clinical information supporting the 
use of IVIG as listed in the British Columbia IVIG 
Utilization Management Handbook and/or in the panel 
recommendations of the Canadian Blood Service 2000 
national consensus conference. Clinical indications 
with no convincing evidence of benefit were defined as 
“not indicated.” These were used for conditions with no 
evidence supporting the use of IVIG or for conditions in 
which IVIG use was deemed ineffective (Selin, 2002; Sher 
et al., 2000). The level of evidence for the labeled and off-
labeled indication is classified as category I, IIa, IIb, or III 
(Sher et al., 2000). 
As clinical outcomes, three parameters were 
documented: the length of hospital stay, mortality, and 
adverse reaction. Length of hospital stay is defined as the 
duration of hospital stay from the day of hospital admission 
until the patient is discharged or deceased. Mortality is 
defined as all-cause mortality. Adverse reaction related to 
IVIG infusion refers to a reaction that occurred during or 
within 48 hours after the infusion. It can be classified as 
mild, moderate, or severe as below (Brennan et al., 2003):
a. Mild reactions
 Symptoms included headache, flushing, muscle 
aches, shivering, feeling sick, itching, urticaria, anx-
iety, lightheadedness, dizziness, or irritability. These 
subsided when the infusion rate was decreased.
b. Moderate reactions
 Symptoms included mild reactions becoming worse 
or other symptoms such as chest pain or wheezing, 
necessitating the infusion to be discontinued.
c. Severe reactions
 Symptoms included moderate reactions persisting 
or becoming worse, or other symptoms such as 
tightness of the throat, severe headache and shaking, 
severe breathlessness or wheezing, severe dizzi-
ness or fainting, sensation of pressure in the chest, 
or collapsing. A severe reaction would require the 
administration of adrenaline and medical attention.
Statistical Package for the Social Sciences version 
22 (SPSS®, Chicago, IL) was used to perform all statistical 
analyses. The indication, dosing regimen, and outcome of 
IVIG administration were descriptively analyzed. The Chi 
Square and Fisher’s Exact tests were used to compare two 
categorical variables, and the Mann-Whitney U test was 
used in comparing the numerical and categorical variables. 
All statistical tests were two-tailed. A p-value of <0.05 
denoted statistical significance. 
RESULTS
A total of 162 patients with prescribed IVIG were 
identified through the computerized pharmacy system 
with only 118 patients having traceable medical records. 
The remaining 44 medical records were untraceable due 
to patients defaulting follow up for 5 years or more. Of the 
118 patients, only 3 did not receive the IVIG therapy due 
to the patients’ worsening clinical condition. Hence, the 
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final sample size was 115 instances of IVIG administered 
to 108 patients from January 1, 2007 to December 31, 
2014. The patient characteristics and clinical data are 
summarized in Table I. 
Out of the 115 cases of IVIG administered, 61 
cases (53%) were used for FDA approved indications 
while another 54 cases (470%) were used for off-labeled 
indications. The indications for IVIG had a category I 
evidence level in 68.9% of cases whereas the remaining 
39.1% had category II and III evidence level (Table II). 
Over the 8-year period, the total IVIG usage was 
1396.42 g. A total of 1007.70 g and 388.72 g of IVIG 
were administered for labeled and off-labeled indications, 
respectively. The dose per course ranged from 0.4 mg/kg to 
2.0 mg/kg with a median of 1.5 mg/kg. Sixty-nine percent 
of IVIG cases (n = 79) were administered in a single dose 
and the remaining 31% (n = 36) were administered as 
divided doses, up to 5 doses, with an interval of 2 to 5 
days per case.
The length of hospital stays for a patient who 
received the IVIG ranged from 1 to 361 days, with a 
median of 23.8 days. After IVIG administration, 99 patients 
(86.1%) were discharged. Sixteen (13.9%) patients died 
but death was not related to IVIG administration. The 
cause of death comprised 15 cases of severe neonatal 
sepsis with underlying prematurity and 1 case of severe 
gastrointestinal bleeding. 
Seven adverse reactions related to the IVIG 
administration were identified: 5 mild cases and 1 case 
each of moderate and severe adverse reactions. Patients 
with mild adverse reactions developed fever during the 
IVIG administration, and the symptom subsided when the 
infusion rate was reduced. Moderate adverse reaction was 
seen in patients who presented with chills, rigors, fever, 
mild bronchospasm, mild tachypnea, and tachycardia, 
which required additional intervention with antipyretic, 
bronchodilator, oxygen and necessitating the termination 
of IVIG infusion. In the severe adverse reaction case, 
the patient presented with general tonic-clonic seizure 
during IVIG infusion and required a loading dose of an 
antiepileptic drug, intubation for airway protection, and 
termination of IVIG infusion. The Naranjo scale was 
used to determine the probability of IVIG-related adverse 
reactions for the 7 cases, and the scores ranged from 5 to 8.
In this study, the patient’s age, body weight, total 
usage of IVIG, specialty, length of hospital stay, and all-
cause mortality were found to be significantly associated 
with the indication being labeled or off-labeled (p<0.001). 
There were no significant association between the 
indication of IVIG with adverse reaction related to IVIG 
infusion, gender and ethnicity (p>0.05) (Table III). 
TABLE I – Patient demographics and clinical data (n=108 
patients)
Parameter n
Courses of IVIG (n) 115
Age, years [median (IQR)] 0.58 (1.98)
Gender , n (%)
Male 65(56.5)
Female 50 (43.5
Body weight, kg [median (IQR)] 6.88 (8.76)
Ethnicity, n (%)
Malay 75 (65.2)
Chinese 33 (28.7)
Indian 2 (1.7)
Others 5 (4.3)
Setting, n (%)
PHDU 69 (60.0)
NICU 44 (38.3)
PICU  2 (1.7)
Specialty, n (%)
Neurology  7 (6.1)
Hematology 31 (27.0)
Immunology  4 (3.4)
Dermatology 25 (21.7)
Neonatology 44 (38.3)
Others 4 (3.4)
Primary diagnosis, n (%)
ITP 31 (27.0)
Neonatal sepsis 31 (27.0)
Kawasaki disease 24 (20.9)
Severe neonatal jaundice (NNJ) secondary 
ABO incompatibility
 8 (7.0)
Primary immunodeficiency disease  3 (2.6)
Guillain-Barré syndrome 2 (1.7)
Perinatal acquired varicella infection 
(prophylaxis)
2 (1.7)
Neonatal autoimmune thrombocytopenia 2 (1.7)
CIDP 2 (1.7)
Multiple sclerosis 1 (0.9)
Acute graft versus host disease (GVHD) 1 (0.9)
Varicella pneumonitis 1 (0.9)
Anti-NMDA receptor encephalitis 1 (0.9)
Acute transverse myelitis  1 (0.9)
Viral myocarditis  1 (0.9)
Toxic epidermal necrolysis (TEN) 1 (0.9)
Acute disseminated encephalomyelitis 
(ADEM)
1 (0.9)
Evan’s syndrome 1 (0.9)
Systemic lupus erythematous (SLE)  1 (0.9)
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DISCUSSION
In our study, nearly half of the IVIG treatment 
given through the years 2007-2014 were for off-labeled 
indications. This value is much higher than those reported 
in the other studies. A study conducted in Singapore 
over a 10-year period in two public pediatric hospitals 
reported that IVIG was used for off-labeled indications 
in only less than 25% of cases (Wu et al., 2013). A study 
on IVIG use in the 10 institutions in Canada from 1997 to 
1999 found that 38% of children received IVIG for off-
labeled indications (Hanna et al., 2003). Another report 
from Spain on the utilization of IVIG from 2000 to 2004 
that included 273 patients found that only 14% of IVIG 
courses were prescribed for off-labeled indications (Badia, 
Cardona, Massanes, 2006). The widespread use of IVIG 
for off-labeled indications, emergence of new therapeutic 
indications, and indefinite duration of use in neurological 
illnesses in addition to immune deficiencies have been 
linked with the shortage of IVIG supply (Provan et al., 
2007). 
In this study, the utilization of IVIG in the adjunctive 
treatment of neonatal sepsis and severe neonatal jaundice 
secondary to ABO incompatibility contributed to the high 
usage of IVIG for off-labeled indications in the study. A 
meta-analysis of 110 cases of neonatal sepsis administered 
with IVIG found a 6-fold reduction in mortality compared 
to controls (Jenson, Pollock, 1997). Another meta-analysis 
TABLE II – Utilization of IVIG by indication and evidence category 
Indication Number of cases (%) Category evidence*
Labeled use
Kawasaki disease 31 (27.0) I
ITP 24 (20.9) I
Primary immunodeficiency 3 (2.6) I
CIDP 2 (1.7) I
Acute GVHD 1 (0.9) IIa
Off-labeled, potentially indicated
Neonatal sepsis 31 (27.0) IIb
Severe NNJ secondary to ABO incompatibilities I
Guillain-Barré syndrome 8 (7.0) I
Perinatal-acquired varicella zoster infection (prophylaxis) 2 (1.7) IIb
Neonatal autoimmune thrombocytopenia 2 (1.7) IIb
Anti-NMDA receptor encephalitis 2 (1.7) III
TEN 1 (0.9) IIb
ADEM 1 (0.9) IIa
Evan’s syndrome 1 (0.9) IIb
Off-labeled, not indicated
SLE 1 (0.9) III
Multiple sclerosis 1 (0.9) IIb
Varicella pneumonitis 1 (0.9) III
Acute transverse myelitis 1 (0.9) III
Viral myocarditis 1 (0.9) III
* Classification of evidence levels (Selin, 2002):
• Category I: Medical conditions for which there is convincing evidence of benefit resulting from IVIG therapy. 
• Category II: Medical conditions for which there is inconclusive evidence of benefit from IVIG therapy, because of either 
conflicting evidence, low level evidence, or limited research, possibly because the condition is rare. Category II is subdivided 
into “a” (high) and “b” (low), depending on whether there is a higher or lower level of evidence of benefit.
• Category III: Medical conditions for which there is convincing evidence that IVIG has no benefit, or for which there is no 
convincing evidence of benefit of IVIG therapy.
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on the assessment of its effectiveness found a significant 
reduction in mortality in infants with suspected or proven 
infection; however, a concern about the small sample sizes 
and study quality was raised (Ohlsson, Lacy, 2015). In 
2011, the International Neonatal Immunotherapy Study 
(INIS) Collaborative Group published a placebo-controlled 
trial on 3493 low-weight infants and found no significant 
difference in the rate of death or major disability at the age 
of 2 years between patients receiving placebo or those under 
IVIG treatment for neonatal sepsis (Brocklehurst et al., 
2011). Based on the evidence from this latest prospective, 
randomized and placebo-controlled trial, the United 
Kingdom clinical guideline on IVIG use had listed neonatal 
sepsis as one of the “not recommended indication” for IVIG 
therapy with grade A recommendation and level Ia evidence 
level (Provan et al., 2011). 
Few studies on neonatal jaundice found the 
beneficial effect of IVIG administration in neonates with 
isoimmune hemolytic jaundice. Two systematic reviews 
demonstrated that IVIG significantly reduced the need for 
exchange transfusion in neonates with hemolytic disease 
of the fetus and newborn (Alcock, Liley, 2002; Gottstein, 
Cooke, 2003). Moreover, exchange transfusion was 
reported to be associated with morbidity and mortality 
(Anderson et al., 2007). 
For all labeled indications, the recommended IVIG 
dose and frequency are according to the guidelines of 
the British Columbia IVIG Utilization Management 
Handbook and the Canadian Blood Service 2000 national 
consensus conference on IVIG. For off-labeled indications, 
IVIG was administered using a variety of dosing regimens 
but still following the usual recommended dose in labeled 
TABLE III – Association between demographics and clinical data with labeled and off-labeled indications
Parameter Labeled (n=61) Off-labeled (n=54) p-value
Age, years [median (IQR)] 1.25 (0.67-2.42) 0.02 (0.01-0.17) <0.001b
Gender, n (%) 0.857a
Male 34 (55.7) 31 (57.4)
Female 27 (44.3) 23 (42.6)
Ethnicity, n (%) 0.335c
Malay 39 (63.9) 36 (66.7)
Chinese 20 (32.8) 13 (24.1)
Indian 2 (3.3) 2 (3.7)
Others 0 3 (5.6)
Body weight, kg [median (IQR)] 9.10 (7.12-11.80) 2.36 (0.96-3.28) <0.001b
Specialty, n (%) <0.001c
Neurology 2 (3.3) 5 (9.3)
Hematology 31 (50.8) -
Immunology 3 (4.9) 1 (1.9)
Dermatology 24 (39.3) 1 (1.9)
Neonatology - 44 (81.5)
Others 1 (1.6) 3 (5.6)
Total usage, g [median (IQR)] 14.00 (9.00-20.00) 2.50 (1.30-3.00) <0.001b
Length of hospital stay (day) 5.00 (3.00-8.00) 15.50 (5.00-53.00) <0.001b
All cause mortality, n (%) <0.001c
Yes 1 (1.6) 15 (27.8)
No 60 (98.4) 39 (72.2)
Adverse reaction, n (%) 0.705c
Yes 3 (4.9) 4 (7.4)
No 58 (95.1) 50 (92.6)
a = Chi Square test; b = Mann-Whitney U test, c = Fisher’s Exact test. *p < 0.05 denoted statistical significant difference. 
IQR = interquartile range
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indications, which ranged from 0.4 g/kg to 2.0 g/kg per 
course in either a single dose or few divided doses (Prasad, 
Chaudhary, 2014). 
The incidence of adverse reaction in this study was 
6.1%, which falls in the range of 3-15% as reported in the 
literature (Goddard, 2008). The Naranjo scale, an adverse 
drug reaction probability scale, was used to assess the 
causality of IVIG-related adverse reaction in 7 reported 
cases in this study. All the 7 cases (5 mild cases, 1 moderate 
case, and 1 severe case) were interpreted as a probable level 
of IVIG infusion-related adverse reaction. The probable 
level of the Naranjo score is defined as the adverse reaction 
that occurred following a reasonable temporal sequence 
after drug administration and a recognized response to the 
suspected drug. It was confirmed by withdrawal but not by 
exposure to the drug and could not be reasonably explained 
by the known characteristics of the patient’s clinical state 
(Naranjo et al., 1981).
In the present study, the indication of IVIG as 
labeled or off-labeled was found to be associated with 
the patient’s age, body weight, specialty, total IVIG 
usage, length of hospital stay, and all-cause mortality 
rate. Neonatal sepsis and severe NNJ secondary to 
ABO incompatibility were the most common off-label 
indications for IVIG administration. Hence, the lower 
total usage of IVIG for off-labeled indications compared 
to the labeled indications could be explained by the lower 
body weight of neonates. Other various factors such as 
underlying illness may contribute to the longer hospital 
stay and higher mortality rate seen in patients receiving 
IVIG for off-label indications. 
In view of the high usage of IVIG for off-label 
indications, a strict approval system for IVIG prescription 
is needed. In many institutions, policies have been 
developed to monitor and control the dispensing process of 
IVIG. In a Spanish institution, the pharmacists assess the 
indication and categorize it upon receipt of prescription for 
IVIG. If the IVIG is requested for off-labeled indications, 
the pharmacist will contact the prescriber to obtain the 
documentation required to request authorization from the 
health authorities for compassionate use (Badia, Cardona, 
Massanes, 2006). A study conducted in Saudi Arabia had 
showed a clear improvement in the ratio of labeled to off-
labeled use and correct dosing for various indications after 
the adoption of an IVIG indication form. Any off-labeled 
indication must obtain approval from the clinical research 
committee (Frayha et al., 1997). Hence, all these strategies 
could be implemented for optimal IVIG utilization in the 
present setting. 
There were several limitations of this study. First, 
there were medical records that could not be traced from 
the years 2007 to 2010. For that reason, the exact usage 
of IVIG could be higher than that reported in this study. 
Second, the length of hospital stays and mortality rate 
could be affected by other comorbidities or coinfection 
present and not just due to the IVIG treatment. 
CONCLUSION
IVIG therapy used in this setting for off-labeled 
indications was high with indications that may not benefit 
from the IVIG therapy due to the lack of strong clinical 
evidence. The patient’s age, body weight, specialty, 
total IVIG usage, length of hospital stays, and all-cause 
mortality rate were found to be associated with IVIG 
indications being labeled or off-labeled, although there 
are other confounding factors that may have influenced 
the results seen. A national policy on the prescription of 
IVIG needs to be urgently developed to guide physicians 
in appropriately prescribing IVIG for pediatric patients. 
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